On July 27, 2026 AstraZeneca reported results for H1 and Q2 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030
Revenue and EPS summary
H1 2026
% Change
Q2 2026
% Change
$m
Actual
CER1
$m
Actual
CER
– Product Sales
28,896
8
5
14,510
5
4
– Alliance Revenue
1,699
31
29
874
34
33
Product Revenue
30,595
9
6
15,384
6
5
Collaboration Revenue
77
(6)
(9)
–
n/m
n/m
Total Revenue
30,672
9
6
15,384
6
5
Reported EPS ($)
3.60
4
3
1.61
2
(2)
Core2 EPS ($)
5.21
12
11
2.63
21
18
Key performance elements for H1 2026
(Growth numbers at constant exchange rates)
● Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from Farxiga US loss of exclusivity and China volume-based procurement
● Core Operating profit and Core EPS increased 11%
● Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK)
● 30 approvals in major regions since Q4 2025 results
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
"In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension.
While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months.
We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030."
Guidance
AstraZeneca reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign exchange rates through 2025.
Total Revenue is expected to increase by a mid-to-high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage
Results highlights
Table 1: Milestones achieved since the prior results announcement
Phase III and other registrational data readouts
Medicine
Trial
Indication
Event
Imfinzi
VOLGA
MIBC not candidates for cisplatin
Primary endpoint met
Imfinzi
EMERALD-2
Adjuvant HCC
Primary endpoint not met
Imfinzi
NILE
1L bladder cancer
Primary endpoint met
sone-ve
CLARITY-Gastric01
2L+ Cldn18.2+ gastric/GEJ cancer
Primary endpoint met
Wainua
CARDIO-TTRansform
ATTR-CM
Primary endpoint not met
Ultomiris
TMA-313
HSCT-TMA (adults)
Primary endpoint not met
Ultomiris
ALXN1210-MG-319
gMG (paediatric)
Primary endpoint met
Regulatory approvals
Medicine
Trial
Indication
Region
Calquence
AMPLIFY
1L CLL (fixed duration)
JP
Datroway
TROPION-Breast02
1L TNBC for patients where immunotherapy is not an option
US
Enhertu
DESTINY-Breast05
High-risk HER2+ early breast cancer (post-neoadjuvant)
US
Enhertu
DESTINY-Breast11
Neoadjuvant HER2+ Stage II or III breast cancer
US
Enhertu
DESTINY-PanTumor02 / DESTINY-Lung01 / DESTINY-CRC02
HER2-positive solid tumours
EU
Etcamah (camizestrant)
SERENA-6
ESR1m HR+ HER2- 1L locally advanced or metastatic breast cancer
EU, JP
Imfinzi
POTOMAC
NMIBC
US
Imfinzi
MATTERHORN
Resectable gastric/GEJ cancer
JP
Orphathys
NCT04923932
3L+ MET+ gastric/GEJ cancer
CN
Truqap
CAPItello-281
PTEN-deficient mHSPC
US
Baxfendy
BaxHTN
Hypertension
US
Fasenra
NATRON
Hypereosinophilic syndrome
US, EU, JP, CN
Regulatory submissions or acceptances* in major regions
Medicine
Trial
Indication
Region
Baxfendy
BaxHTN / Bax24 / BaxAsia
Hypertension
JP
tozorakimab
OBERON / TITANIA / MIRANDA / PROSPERO
COPD
EU, CN
Ultomiris
I CAN
IgAN
US, JP
efzimfotase alfa
MULBERRY / CHESTNUT / HICKORY
HPP
JP
* US, EU and China regulatory entries in this table denote filing acceptance
Other pipeline updates
Table 2: Key elements of financial performance: Q2 2026
For the quarter
Reported
Change
Core
Change
ended 30 June
$m
Act
CER
$m
Act
CER
Product Revenue
15,384
6
5
15,384
6
5
● See Tables 3, 7, 23, 24 and 25 for further details of Product Revenue, Product Sales and Alliance Revenue
Collaboration Revenue
—
n/m
n/m
—
n/m
n/m
● See Tables 4 and 26 for further details of Collaboration Revenue
Total Revenue
15,384
6
5
15,384
6
5
● See Tables 5 and 6 for Total Revenue by Therapy Area and by region
Gross Margin (%)
84
+1pp
—
84
+1pp
+1pp
+ Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue
– Pricing headwinds, including those driven by loss of exclusivity and VBP in China
R&D expense
4,053
14
13
3,662
6
5
● Core R&D: 24% of Total Revenue
+ Increasing number of trials, and patients in those trials
+ Investments in transformative technologies
+ Addition of R&D projects from business development
+ Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials
SG&A expense
5,651
16
14
4,050
7
4
● Core SG&A: 26% of Total Revenue
+ Investment to support ongoing and future launches
Other operating income and expense4
152
92
93
152
>2x
>2x
+ Various partner milestones
Operating profit
3,164
(10)
(13)
5,158
12
10
Operating Margin (%)
21
-4pp
-4pp
34
+2pp
+2pp
Net finance expense
355
(4)
(8)
340
13
8
+
Lower interest income on short-term deposits
– Reported Net finance expense benefitted from a lower discount unwind on contingent consideration liabilities
Tax rate (%)
10
-11pp
-11pp
15
-6pp
-6pp
– Benefit from adjustments to deferred tax assets, as a result of certain internal legal entity changes.
● Variations in the tax rate can be expected between periods
EPS ($)
1.61
2
(2)
2.63
21
18
For dollar values in this table, the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).
In the table above, R&D expense, SG&A expense and Net finance expense are displayed as positive numbers. The plus and minus symbols next to comments denote the directional impact of the item being discussed. For example, a plus symbol next to a comment about an R&D item indicates that the item increased R&D expenditure relative to the prior year period.
Corporate and business development
Dizal Pharmaceutical Co
In July 2026, AstraZeneca entered into an exclusive license agreement with Dizal Pharmaceutical Co (Dizal), Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for patients with lung cancer.
AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy, which is approved in the US and China for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
AstraZeneca will make an upfront payment to Dizal of $600m and additional payments of up to $900m upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances.
Sino Biopharmaceutical
In July 2026, AstraZeneca and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited, entered into an exclusive licence agreement for the development, manufacturing and commercialisation of CTTQ’s PDE3/4 inhibitor, TQC3721, which is being developed for respiratory indications.
Sino Biopharmaceutical Limited is eligible to receive an upfront payment of $200m, with additional development, regulatory and sales milestones up to $1.9bn, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products.
The agreement is subject to customary closing conditions, including regulatory clearances.
Sustainability highlights
In July 2026, AstraZeneca hosted a call for investors to discuss the latest developments in its Sustainability strategy. A replay of the call is available on astrazeneca.com.
Reporting calendar
The Company intends to publish its 9M and Q3 2026 results on 30 October 2026.
Conference call
A conference call and webcast for investors and analysts will begin today, 27 July 2026, at 11:45 UK time. Details can be accessed via astrazeneca.com.
Notes
1.
Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
2.
Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document.
3.
The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement.
4.
Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group’s financial statements.
Revenue drivers
Table 3: Product Revenue (PR) by medicine
H1 2026
% Change
Q2 2026
% Change
$m
% Total
Actual
CER
$m
% Total
Actual
CER
Tagrisso
3,775
12
8
6
1,941
13
7
6
Imfinzi
3,548
12
31
29
1,854
12
27
27
Calquence
1,944
6
19
16
1,022
7
17
16
Lynparza
1,610
5
3
(1)
829
5
(1)
(3)
Enhertu
1,719
6
36
32
888
6
33
31
Zoladex
631
2
7
3
316
2
7
3
Truqap
431
1
43
41
233
2
37
37
Imjudo
160
1
(6)
(7)
83
1
(7)
(7)
Datroway
98
–
>6x
>6x
55
–
>5x
>5x
Etcamah
3
–
n/m
n/m
3
–
n/m
n/m
Other Oncology
204
1
(6)
(8)
102
1
(4)
(5)
Oncology PR
14,123
46
18
15
7,326
48
16
15
Farxiga
3,998
13
(5)
(11)
1,804
12
(16)
(19)
Crestor
686
2
8
4
332
2
4
1
Lokelma
419
1
28
26
221
1
26
26
Seloken
337
1
9
5
157
1
6
2
Brilinta
186
1
(64)
(66)
80
1
(62)
(63)
Wainua
121
–
44
44
70
–
58
58
roxadustat
57
–
(63)
(64)
14
–
(81)
(82)
Baxfendy
3
–
n/m
n/m
3
–
n/m
n/m
Other CVRM
206
1
(25)
(28)
91
1
(34)
(35)
Cardiovascular, Renal & Metabolism PR
6,013
20
(8)
(12)
2,772
18
(15)
(18)
Symbicort
1,418
5
(1)
(4)
671
4
(6)
(8)
Fasenra
1,053
3
14
12
570
4
14
13
Breztri
699
2
20
17
346
2
22
20
Tezspire
694
2
43
40
390
3
46
45
Saphnelo
380
1
25
24
209
1
25
24
Pulmicort
269
1
2
(3)
120
1
13
9
Airsupra
87
–
24
23
50
–
19
18
Other R&I
150
–
(13)
(15)
75
–
11
8
Respiratory & Immunology PR
4,750
16
12
9
2,431
16
13
11
Beyfortus
194
1
(18)
(18)
79
1
(37)
(37)
FluMist
26
–
>2x
>2x
18
–
79
78
Other ID
92
–
(43)
(47)
34
–
(31)
(34)
Infectious Disease PR
312
1
(24)
(26)
131
1
(29)
(30)
Ultomiris
2,584
8
16
14
1,314
9
12
12
Soliris
778
3
(20)
(22)
389
3
(27)
(28)
Strensiq
1,053
3
41
40
536
3
36
36
Koselugo
347
1
26
21
177
1
29
27
Other Rare Disease
149
–
32
25
74
–
36
33
Rare Disease PR
4,911
16
13
11
2,490
16
9
8
Other Medicines PR
486
2
(6)
(8)
234
2
(4)
(6)
Product Revenue
30,595
100
9
6
15,384
100
6
5
Alliance Revenue included above:
Enhertu
1,058
3
27
24
550
4
26
24
Tezspire
372
1
31
31
218
1
41
41
Beyfortus
123
–
12
12
32
–
14
14
Datroway
93
–
>6x
>6x
51
–
>4x
>4x
Other royalty revenue
51
–
10
10
22
–
(4)
(4)
Other Alliance Revenue
2
–
(22)
(22)
1
–
(42)
(42)
Alliance Revenue
1,699
6
31
29
874
6
34
33
Table 4: Collaboration Revenue
H1 2026
% Change
Q2 2026
% Change
$m
Actual
CER
$m
Actual
CER
Farxiga: sales milestones
44
(43)
(45)
–
n/m
n/m
Crestor: sales milestones
32
n/m
n/m
–
n/m
n/m
Others
1
n/m
n/m
–
n/m
n/m
Collaboration Revenue
77
(6)
(9)
–
n/m
n/m
Table 5: Total Revenue by Therapy Area
H1 2026
% Change
Q2 2026
% Change
$m
% Total
Actual
CER
$m
% Total
Actual
CER
Oncology
14,124
46
18
15
7,327
48
16
15
– Cardiovascular, Renal & Metabolism
6,089
20
(8)
(12)
2,772
18
(15)
(18)
– Respiratory & Immunology
4,750
15
12
9
2,431
16
13
11
– Infectious Disease
312
1
(24)
(26)
131
1
(29)
(30)
BioPharmaceuticals
11,151
36
(1)
(5)
5,334
35
(5)
(7)
Rare Disease
4,911
16
13
11
2,490
16
9
8
Other Medicines
486
2
(7)
(9)
233
2
(7)
(8)
Total Revenue
30,672
100
9
6
15,384
100
6
5
Table 6: Total Revenue by region
H1 2026
% Change
Q2 2026
% Change
$m
% Total
Actual
CER
$m
% Total
Actual
CER
US
12,890
42
8
8
6,686
43
6
6
– Emerging Markets ex. China
4,809
16
15
10
2,334
15
14
11
– China
3,510
11
–
(5)
1,587
10
(7)
(13)
Emerging Markets
8,319
27
8
3
3,921
25
4
–
Europe
6,822
22
17
8
3,417
22
11
7
Established RoW
2,641
9
3
5
1,361
9
4
8
Total Revenue
30,672
100
9
6
15,384
100
6
5
Table 7: Product Revenue by region
H1 2026
% Change
Q2 2026
% Change
$m
% Total
Actual
CER
$m
% Total
Actual
CER
US
12,889
42
8
8
6,685
43
6
6
– Emerging Markets ex. China
4,809
16
15
10
2,334
15
14
11
– China
3,510
11
–
(5)
1,587
10
(7)
(13)
Emerging Markets
8,319
27
8
3
3,921
25
4
–
Europe
6,822
22
17
8
3,417
22
11
7
Established RoW
2,565
8
4
6
1,361
9
4
9
Total Product Revenue
30,595
100
9
6
15,384
100
6
5
Total Revenue by Medicine
Oncology
Tagrisso
H1 2026
Total
% Change
● Strong demand growth across indications and key regions, positioned as backbone
$m
Revenue
Actual
CER
across all stages of EGFRm NSCLC. Leading combination in 1L NSCLC (FLAURA2)
US
1,579
10
10
● Robust underlying demand
Emerging Markets
1,048
4
–
● More competitive environment in China in a slowing EGFRm TKI market
Europe
769
17
8
Established RoW
379
(1)
2
● Recent competitor entrant
Total
3,775
8
6
Imfinzi
H1 2026
Total
% Change
● Strong demand growth across all regions from existing indications and new
$m
Revenue
Actual
CER
launches
US
2,008
28
28
● Demand growth led by new GI and GU launches (MATTERHORN, NIAGARA)
Emerging Markets
398
35
32
● Strong growth in GI (HIMALAYA, TOPAZ) including new launches (MATTERHORN)
Europe
781
45
34
● Early momentum for new lung (ADRIATIC), GI (MATTERHORN) and GU (NIAGARA) launches
Established RoW
361
15
20
● Demand growth from new launches across GYN (DUO-E), GU (NIAGARA) and lung (ADRIATIC, AEGEAN)
Total
3,548
31
29
Calquence
H1 2026
Total
% Change
● Sustained BTKi leadership in front-line CLL with launch momentum across
$m
Revenue
Actual
CER
finite use for 1L CLL (AMPLIFY) and 1L MCL (ECHO)
US
1,286
18
18
● Strong demand growth from ongoing leadership in front-line CLL BTKi market
Emerging Markets
137
33
26
Europe
442
20
11
● Further expansion in finite use for 1L CLL and 1L MCL
Established RoW
79
9
7
Total
1,944
19
16
Lynparza
H1 2026
Total
% Change
$m
Revenue
Actual
CER
● Global leadership in mature first-generation PARPi market
US
659
(4)
(4)
● Demand growth offset by channel mix and inventory destocking
Emerging Markets
343
6
(1)
● Affected by generic competition in China and VBP implementation
Europe
480
13
4
● Continued uptake in prostate (PROpel) and breast (OlympiA) indications
Established RoW
128
1
3
Total
1,610
3
(1)
Enhertu
Combined sales of Enhertu, recorded by Daiichi Sankyo and AstraZeneca, amounted to $2,961m in H1 2026 (H1 2025: $2,289m). US in-market sales, recorded by Daiichi Sankyo, amounted to $1,440m in H1 2026 (H1 2025: $1,128m). For periods up to and including Q3 2025, AstraZeneca’s mid-single-digit percentage royalty on Daiichi Sankyo’s sales in Japan is recorded in Europe; from Q4 2025 this royalty is recorded in Established RoW.
H1 2026
Total
% Change
● Standard-of-care in HER2-positive (DESTINY-Breast03) and HER2-low
$m
Revenue
Actual
CER
(DESTINY-Breast04) metastatic breast cancer, early uptake in other cancers
US
694
28
28
● Ongoing adoption in 1L HER2-positive breast cancer (DESTINY-Breast09)
Emerging Markets
528
45
41
● Continued adoption post-NRDL enlistment of HER2-positive and HER2-low breast cancer from 1 January 2025
Europe
401
28
18
● Further demand growth in chemotherapy naïve HER2-low breast cancer
Established RoW
96
>2x
>2x
Total
1,719
36
32
Other Oncology medicines
H1 2026
Total
% Change
$m
Revenue
Actual
CER
Zoladex
632
8
3
● Growth across Emerging Markets
Truqap
431
43
41
● Achieved peak share in second-line biomarker-altered metastatic breast cancer
Imjudo
160
(6)
(7)
● Continued GI (HIMALAYA) growth ex-US, offset by US destocking and lower demand in some markets
Datroway
98
>7x
>6x
● Continued uptake in breast cancer and EGFRm later-line lung cancer
● Combined global sales by AstraZeneca and Daiichi Sankyo: $225m (H1 2025: $45m)
Etcamah
3
n/m
n/m
● Sales from first launch markets
Other Oncology
204
(6)
(8)
● Generic erosion across markets
Other Oncology includes $14m of Total Revenue from Orpathys, partnered with HUTCHMED.
BioPharmaceuticals – Cardiovascular, Renal & Metabolism
Farxiga
H1 2026
Total
% Change
● Growth impacted by US LoE and China VBP
$m
Revenue
Actual
CER
US
668
(17)
(17)
● Multiple generics launched in Q2 2026
Emerging Markets
1,618
(6)
(13)
● Affected by generic competition and VBP implementation in China in Q1 2026
Europe
1,586
10
1
● Demand growth offset by generic entry in the UK in Q3 2025
Established RoW
169
(44)
(45)
● Generic T2D entry in Japan in Q4 2025. Milestone receipt in Q1 2026
Total
4,042
(6)
(11)
Other CVRM medicines
H1 2026
Total
% Change
$m
Revenue
Actual
CER
Crestor
719
13
9
● Growth driven by Emerging Markets and Est. RoW. Milestone receipt in Q1 2026
Lokelma
419
28
26
● Strong growth in all major regions
Seloken
337
9
5
● Growth driven by Emerging Markets
Brilinta
186
(64)
(66)
● Decline driven by generic entry in the US and Europe in Q2 2025
Wainua
121
44
44
● Demand growth in ATTR-PN and geographic expansion
roxadustat
57
(63)
(64)
● Affected by generic competition in China and VBP implementation in Q1 2026
Baxfendy
3
n/m
n/m
● US launch in hypertension in Q2 2026
Other CVRM
206
(25)
(28)
● Generic erosionBioPharmaceuticals – Respiratory & Immunology
Symbicort
H1 2026
Total
% Change
● Market leader in ICS/LABA class with increasing generic competition
$m
Revenue
Actual
CER
US
545
(9)
(9)
● New generic competitor entered the market
Emerging Markets
417
4
–
Europe
296
9
1
Established RoW
160
(5)
(8)
Total
1,418
(1)
(4)
Fasenra
H1 2026
Total
% Change
● Expanded severe eosinophilic asthma market share leadership in IL-5 class,
$m
Revenue
Actual
CER
further fuelled by accelerated EGPA indication launches
US
594
7
7
● Strong demand with expanded IL-5 class leadership partially offset by Q1 inventory movement and gross-to-net adjustments
Emerging Markets
92
75
69
● Strong China uptake post Q1 2026 NRDL listing with growth in other key markets
Europe
258
13
4
● Increased leadership in severe eosinophilic asthma partially offset by pricing
Established RoW
109
31
33
● Strong growth supported by EGPA in Japan
Total
1,053
14
12
Breztri
H1 2026
Total
% Change
● Fastest growing medicine within the expanding FDC triple class (ICS/LABA/LAMA)
$m
Revenue
Actual
CER
US
309
5
5
● Consistent share growth offset by unfavourable gross-to-net adjustments.
● Approval for asthma in April 2026
Emerging Markets
208
34
27
● Market share leadership within FDC triple class in China
Europe
127
45
34
● Sustained growth from market share gains
Established RoW
55
24
24
Total
699
20
17
Tezspire
Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $1,150m in H1 2026 (H1 2025: $826m).
H1 2026
Total
% Change
● Sustained demand growth in severe asthma with launch momentum across
$m
Revenue
Actual
CER
multiple markets
US
372
31
31
● Continued strong demand growth in severe asthma and launch of CRSwNP
Emerging Markets
44
>2x
>2x
● Strong continued uptake
Europe
202
57
46
● Continued new-to-brand leadership across multiple markets and market growth
Established RoW
75
39
43
Total
694
43
40
Other R&I medicines
H1 2026
Total
% Change
$m
Revenue
Actual
CER
Saphnelo
380
25
24
● Strong US demand growth, ongoing launches in Europe and Established RoW
Pulmicort
269
2
(3)
● Continued pressure in China, Europe, and Established RoW
Airsupra
87
24
23
● US demand volume growth
Other R&I
150
(13)
(15)
BioPharmaceuticals – Infectious Disease
Beyfortus Total Revenue reflects the sum of Product Sales from AstraZeneca’s sales of manufactured product to Sanofi, and Alliance Revenue from AstraZeneca’s share of gross profits and royalties on sales in major markets outside the US.
H1 2026
Total
% Change
$m
Revenue
Actual
CER
Beyfortus
194
(18)
(18)
● Partner’s adjustment of inventory levels
FluMist
26
>2x
>2x
Other ID
92
(43)
(47)
● Other includes Synagis, which declined due to competition from Beyfortus
Rare Disease
Ultomiris
Ultomiris Total Revenue includes sales of Voydeya, which is approved as an add-on treatment to Ultomiris and Soliris for the ~20-30% of PNH patients who experience clinically significant EVH.
H1 2026
Total
% Change
● Growth due to patient demand, both naïve to C5 medicines and conversion from
$m
Revenue
Actual
CER
Soliris across all indications (gMG, NMOSD, aHUS and PNH)
US
1,398
10
10
● Demand growth across indications, including within the competitive gMG and PNH landscapes
Emerging Markets
190
68
65
● Expansion into new markets and growth in patient demand
Europe
605
22
12
● Demand growth following launches; competition in gMG and PNH
Established RoW
391
13
17
● Continued conversion and strong patient demand
Total
2,584
16
14
Soliris
H1 2026
Total
% Change
● Decline driven by conversion of patients to Ultomiris across all indications,
$m
Revenue
Actual
CER
competition in gMG and PNH
US
414
(27)
(27)
● Affected by biosimilar pressure
Emerging Markets
248
10
6
● Growth from launches
Europe
61
(46)
(50)
● Affected by biosimilar pressure in PNH and aHUS
Established RoW
55
(20)
(21)
Total
778
(20)
(22)
Strensiq
H1 2026
Total
% Change
● Growth driven by continued HPP patient demand
$m
Revenue
Actual
CER
US
859
47
47
Emerging Markets
65
30
13
Europe
68
20
10
● Demand growth following new launches
Established RoW
61
10
14
Total
1,053
41
40
Other Rare Disease medicines
H1 2026
Total
% Change
$m
Revenue
Actual
CER
Koselugo
347
26
21
● Continued patient demand and geographic expansion. Strong uptake following launch of adult indication. US growth offset by competitive pressures
Other Rare Disease
149
32
25
● Other Rare Disease medicines include Kanuma and Beyonttra (JP only)
Other Medicines
H1 2026
Total
% Change
$m
Revenue
Actual
CER
Other Medicines
486
(7)
(9)
● Generic erosionR&D progress
This section covers R&D events and milestones that occurred from 29 April 2026 up to and including 26 July 2026. A comprehensive view of AstraZeneca’s pipeline of medicines in human trials can be found in the latest Clinical Trials Appendix, available on AstraZeneca’s investor relations webpage. The Clinical Trials Appendix includes tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the pipeline.
Oncology
AstraZeneca presented new data across its diverse portfolio of cancer medicines at one major medical congress since the prior results announcement: the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2026 (ASCO) (Free ASCO Whitepaper). At this meeting, more than 85 abstracts were presented featuring 23 approved and potential new medicines including 25 oral presentations.
Calquence
Approval
JP
AMPLIFY
June 2026
New disclosure
● As time-limited treatment (fixed-duration regimen) in combination with venetoclax for the treatment of adult patients with chronic lymphocytic leukaemia (including small lymphocytic lymphoma).
Datroway
Approval
US
TROPION-Breast02
May 2026
● Unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy.
CHMP opinion
EU
TROPION-Breast02
June 2026
● 1st-line treatment of unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy.
Enhertu
Approval
US
DESTINY-Breast05
May 2026
● As adjuvant treatment for HER2-positive (IHC 3+ or ISH+) breast cancer with residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.
Approval
US
DESTINY-Breast11
May 2026
● As neoadjuvant treatment for HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorised test followed by a taxane, trastuzumab, and pertuzumab.
Approval
EU
DESTINY-PanTumor02 / DESTINY-Lung01 / DESTINY-CRC02
June 2026
● As monotherapy for the treatment of unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and who have no satisfactory treatment options.
CHMP opinion
EU
DESTINY-Breast09
July 2026
New disclosure
● In combination with pertuzumab for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Etcamah (camizestrant)
Approval
EU
SERENA-6
July 2026
● In combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) for ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor.
Approval
JP
SERENA-6
June 2026
New disclosure
● Inoperable or recurrent hormone receptor-positive, HER2-negative breast cancer with ESR1 mutation confirmed during endocrine therapy and no disease progression has been observed.
Imfinzi
Phase III readout
VOLGA
May 2026
● Perioperative treatment with Imfinzi in combination with neoadjuvant enfortumab vedotin demonstrated statistically significant and clinically meaningful improvements in EFS and OS in patients with MIBC versus standard of care.
Phase III data presentation
EMERALD-3
June 2026
● Positive results from the EMERALD-3 Phase III trial demonstrated the STRIDE regimen combined with lenvatinib and TACE demonstrated a 30% reduction in the risk of disease progression or death versus TACE alone (PFS HR 0.70; 95% CI 0.57-0.86; p=0.0007). The median PFS was 13.0 months for this regimen versus 9.8 months for TACE. For the secondary endpoint of OS, a positive trend was observed in favour of the STRIDE regimen with lenvatinib and TACE versus TACE alone (HR 0.84; 95% CI 0.65-1.09; p=0.1814).
Approval
US
POTOMAC
May 2026
● In combination with Bacillus Calmette-Guérin is indicated for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer.
Approval
JP
MATTERHORN
June 2026
New disclosure
● In combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant Imfinzi monotherapy, is indicated for the treatment of adults with resectable gastric or gastroesophageal junction adenocarcinoma.
Regulatory update
EU
POTOMAC
July 2026
New disclosure
● Voluntary withdrawal of the Type II variation application for Imfinzi in combination with Bacillus Calmette-Guérin for the treatment of BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on the POTOMAC Phase III trial.
Phase III readout
EMERALD-2
Q2 2026
New disclosure
● The EMERALD-2 Phase III trial of Imfinzi in combination with bevacizumab as adjuvant therapy after curative resection or ablation in HCC patients at high risk of recurrence did not meet the primary endpoint of recurrence-free survival versus placebo. The safety and tolerability profiles for Imfinzi monotherapy and in combination with bevacizumab were consistent with the established profiles of each product.
Phase III readout
NILE
Q2 2026
New disclosure
● Positive high-level results from the NILE Phase III trial showed that one dual primary endpoint was met, with Imfinzi plus chemotherapy demonstrating a statistically significant and clinically meaningful improvement in OS versus chemotherapy as 1st-line treatment for patients with PD-L1 high unresectable, locally advanced or metastatic urothelial cancer. Imfinzi plus Imjudo with chemotherapy did not meet the other dual primary endpoint of OS versus chemotherapy in the same PD-L1 high population. The safety profiles for Imfinzi and Imjudo were consistent with their known profiles.
Phase III update
PACIFIC-8
Q2 2026
New disclosure
● Recruitment into the PACIFIC-8 Phase III trial of Imfinzi in combination with domvanalimab versus Imfinzi alone in patients with PD-L1 positive Stage III unresectable NSCLC has been discontinued based on results of the Arcus/Gilead Phase III trials STAR-121 and STAR-221 containing domvanalimab. There were no new safety signals in PACIFIC-8.
Lynparza
Regulatory update
CN
PROfound
June 2026
New disclosure
● Label revision to remove PROfound indication (BRCAm mCRPC) based on conditional approval lapse; Post Marketing Commitment not fulfilled.
Orpathys
Approval
CN
NCT04923932
July 2026
● Locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments.
sonesitatug vedotin (sone-ve)
Phase III readout
CLARITY-Gastric01
July 2026
New disclosure
● The CLARITY-Gastric01 global Phase III trial for sonesitatug vedotin had dual primary endpoints of OS in 3rd and later-line treatment and progression-free survival (PFS) in the overall trial population.
● The trial met the dual primary endpoint of OS in 3rd and later-line treatment, and a key secondary endpoint of OS in the overall trial population of patients treated in the 2nd and later-line setting, demonstrating a statistically significant and highly clinically meaningful improvement.
● For the second dual primary endpoint of PFS as assessed by blinded independent central review, results showed a trend toward improved PFS in patients treated in the 2nd and later-line setting but did not reach statistical significance.
Truqap
Approval
US
CAPItello-281
June 2026
● In combination with abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer.
BioPharmaceuticals – Cardiovascular, Renal & Metabolism
Baxfendy
Approval
US
BaxHTN
May 2026
● For the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled.
elecoglipron
Data presentation
ADA
VISTA/SOLSTICE
June 2026
● In the VISTA Phase IIb trial in adults with obesity or overweight and at least one comorbidity, elecoglipron demonstrated a clinically meaningful and statistically significant average reduction in body weight of 10.5% at 26 weeks compared to 0.6% with placebo, a dual primary endpoint. Weight loss in participants receiving elecoglipron did not plateau, reaching 11.8% at 36 weeks (75mg) versus 0.3% with placebo. In the SOLSTICE Phase IIb trial in patients with type 2 diabetes, elecoglipron demonstrated a clinically meaningful and statistically significant average reduction in HbA1c of 1.9% from baseline at 26 weeks compared to 0.2% with placebo, the trial’s primary endpoint.
Wainua
Phase III readout
CARDIO-TTRansform
July 2026
● Wainua in patients with ATTR-CM did not meet the primary efficacy endpoint of the composite outcome of CV mortality and recurrent CV clinical events up to 140 weeks compared with placebo. In a prespecified subgroup analysis of patients treated with Wainua monotherapy as compared to placebo, fewer primary composite events (CV mortality and recurrent CV events) were observed and this result was nominally significant. In patients who were on stabiliser therapy at baseline, no treatment effect was observed.
BioPharmaceuticals – Respiratory & Immunology
Breztri
CHMP opinion
EU
KALOS/LOGOS
July 2026
● Maintenance treatment of asthma in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose inhaled corticosteroid and long-acting beta2-agonist.
Fasenra
Approval
US
NATRON
May 2026
New disclosure
● For the treatment of adult and paediatric patients aged 12 years and older with HES without an identifiable non-hematologic secondary cause.
Approval
JP
NATRON
May 2026
New disclosure
● For the treatment of HES in adult and paediatric patients aged 12 years and older.
Approval
CN
NATRON
May 2026
New disclosure
● For the treatment of HES in adults and adolescents aged 12 years and older without a definite non-hematologic secondary cause.
Approval
EU
NATRON
July 2026
New disclosure
● Add on treatment for adult and adolescent patients aged 12 years and older weighing at least 35 kg with inadequately controlled HES without an identifiable non-haematologic secondary cause.
Rare Disease
anselamimab
Data presentation
ASCO
CARES
June 2026
● The global CARES Phase III clinical programme, in a prespecified subgroup analysis of patients with kappa predominant light chain isotype, anselamimab improved survival by 62%, measured by all-cause mortality (HR 0.38; 95% CI 0.17-0.86; nominal p=0.012), and reduced the frequency of cardiovascular hospitalisations by 71% (incidence risk ratio 0.29; 95% CI 0.10-0.87; nominal p=0.028), compared to placebo.
eneboparatide
Data presentation
ECE
CALYPSO
May 2026
● The CALYPSO Phase III trial showed that 31.1% of patients treated with eneboparatide met the composite primary endpoint, achieving sCa within normal range (8.3-10.6 mg/dL) and independence from oral supplements at week 24, compared with 5.9% of patients in the placebo group (eneboparatide: n=41/132; placebo: n=4/68; p=0.0001) in patients with chronic hypoparathyroidism.
efzimfotase alfa
Data presentation
ICCBH
MULBERRY
June 2026
● Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa achieved an observed median RGI-C Score of 1.67 at week 25 compared to an observed median score of 0 in the placebo group, with a median difference of 1.67 (95% CI: 0.66, 2.00; p=0.0003) in children (2 to <12 years of age) with HPP.
Data presentation
ICCBH
CHESTNUT
June 2026
● In the CHESTNUT trial, efzimfotase alfa demonstrated a similar incidence of treatment-emergent adverse events at week 25 in children (2 to <12 years of age) with HPP who switched from Strensiq (90.5%) compared to those who remained on Strensiq (86.4%) with a favourable safety profile.
Ultomiris
Data presentation
ERA
I CAN
June 2026
● Positive results from a prespecified interim analysis of the I CAN Phase III, Ultomiris demonstrated a 46.6% reduction in 24-hour UPCR from baseline (95% CI: 39.0%, 53.2%) at week 34, compared to 5.6% (95% CI: -4.9%, 15.0%) in patients with IgAN receiving placebo, resulting in a placebo-adjusted treatment effect of 43.4% (95% CI: 33.5%, 51.8%; p<0.0001) in patients.
Phase III trial update
ALXN1210-TMA-313
July 2026
New disclosure
● High-level results showed that Ultomiris did not achieve statistical significance for the primary endpoint of event-free survival through 26 weeks compared to placebo in adults and adolescents (aged 12 years or older) with thrombotic microangiopathy after haematopoietic stem cell transplant. The primary endpoint was defined as the time from randomisation until TMA-related clinical worsening or death, whichever occurred first. Ultomiris showed a trend toward treatment benefit in adults and adolescents , discussions with health authorities are ongoing regarding the interpretation of these data, including in the context of real-world evidence.
● In paediatric patients with HSCT-TMA, the ALXN1210-TMA-314 open-label Phase III trial of Ultomiris, we are advancing regulatory filings, based on data from the open-label Phase III trial we reported in 2025, and data from an external control study.
Phase III readout
ALXN1210-MG-319
July 2026
New disclosure
● High-level results from ALXN1210-MG-319 Phase III, single arm, open label trial evaluating Ultomiris in paediatric and adolescent patients with generalised myasthenia gravis met its primary endpoints and demonstrated efficacy consistent with that seen in the adult population (ALXN1210-MG-306), with safety consistent with the established profile of Ultomiris.
Sustainability
Sustainability highlights
AstraZeneca received several prestigious recognitions for its sustainability leadership in the quarter. TIME Magazine named AstraZeneca one of the World’s Most Sustainable Companies for the third consecutive year, ranking it as the third most sustainable pharmaceutical company, and the Financial Times featured AstraZeneca in its 2026 Europe’s Climate Leaders list for the sixth consecutive year, ranking it as the top pharmaceutical company for climate action. AstraZeneca also ranked in Gartner’s Supply Chain Top 25, which includes ESG criteria, for the fourth consecutive year and as the highest-ranked pharmaceutical company for the second year running.
At the 79th World Health Assembly (WHA) in Geneva, Switzerland, the AstraZeneca delegation led by Chair Michel Demaré and EVP International, Iskra Reic, engaged more than 100 stakeholders, including over 30 government officials, to advance action related to health equity and health systems resilience. The delegation participated in over 10 government and partner-co-hosted events, including a flagship Lung Health event; a panel on implementing the WHO’s 2025 Rare Disease resolution; a roundtable on rare disease in Asia; and a roundtable on Chronic Kidney Diseases.
Climate and nature
The Company achieved milestones related to clean heat:
–
In March, AstraZeneca launched a supplier decarbonisation programme with Secaro and ERM to support clean heat adoption across its supplier network, which was profiled in Forbes.
–
In April, the renewable natural gas (RNG) facility supplying AstraZeneca’s US R&D and manufacturing sites was formally commissioned, with Virginia state leaders in attendance.
–
In June, a partnership to supply renewable liquified natural gas (RLNG) to the Company’s Puerto Rico site was announced.
The Company achieved gold status in the Government of Canada’s Environment and Climate Change Net-Zero Challenge, becoming the first pharmaceutical company in Canada to reach this tier.
In the UK, AstraZeneca was named Green Business of the Year by the British Business Awards and also received the 2026 Society for Chemical Industry (SCI) Sustainability Award for reducing solvent use, in recognition of the Company’s setting a new benchmark in environmental stewardship in pre-clinical chemistry.
Health equity
AstraZeneca advanced its focus on health equity in science through two strategic genomics partnerships which provide access to large-scale datasets representing more than 520,000 participants globally, including from underserved communities.
In the US, the Company delivered its first clinical trial awareness event for underserved areas in Baltimore. AstraZeneca’s global clinical trial website was made available in Portuguese and Vietnamese, in alignment with Company’s Health equity priority countries.
In May 2026, Healthy Heart Africa (HHA) formalised its first Memorandum of Understanding with Morocco’s Ministry of Health, marking a strategic partnership with PATH to expand into Morocco.
Through the Young Health Programme (YHP), AstraZeneca continued to strengthen community impact, expanding work with NGO partners to advance NCD prevention and health equity for young people. This included partnerships in Colombia, Costa Rica, Estonia, Kenya, Malaysia and Spain. The programme received external recognition in Vietnam with a Certificate of Merit by the Ministry of Education & Training.
By July, AstraZeneca’s Cancer Care Africa (CCA) initiative had supported cancer screening for over 328,000 patients and trained over 28,000 oncology healthcare professionals, since 2024. Key CCA achievements during the first half of 2026 include an international multidisciplinary team (MDT) collaboration to reduce variability in Hepatocellular Carcinoma (HCC) care across Ministry of Health (MoH) centres in Egypt and expansion of local diagnostic capacity in Kenya to now include BRCA testing.
Health systems resilience
Following the publication of the Canada roadmap in March, the Partnership for Health System Sustainability and Resilience (PHSSR) launched new country policy roadmaps on acting early on NCDs for France, Germany, Greece, Italy, and Japan. AstraZeneca supported through input on evidence-based, country-specific policy recommendations and activation of key stakeholders during launch.
In Germany, the PHSSR roadmap on early action for NCDs underscored the importance of ensuring broad access to innovative medicines in the context of ongoing health reforms, covered in the Tagesspiegel Background.
AstraZeneca announced a Memorandum of Understanding (MOU) with Northern Ireland’s Department of Health, Department for the Economy and the Health Innovation Research Alliance Northern Ireland (HIRANI), to facilitate earlier, community-based intervention to improve patient outcomes and address health inequalities.
How we do business
During Learning at Work Week in May, AstraZeneca highlighted its ‘3Es’ framework Education, Exposure and Experience, which supports colleagues to build skills through formal learning and real-world experience tailored to their roles, learning styles and career aspirations.
For the third year in a row, AstraZeneca was named The Times’ Graduate Employer of Choice in R&D.
Operating and financial review
Reporting currency
All narrative on growth and results in this section is based on actual exchange rates, and financial figures are in US$ millions ($m), unless stated otherwise.
Reporting period
The performance shown in this announcement covers the six-month period to 30 June 2026 (‘H1 2026’) compared to the six-month period to 30 June 2025 (‘H1 2025’), and the three-month period to 30 June 2026 (‘the quarter’ or ‘Q2 2026’) compared to the three-month period to 30 June 2025 (‘Q2 2025’), unless stated otherwise.
Non-GAAP financial measures
Core financial measures, EBITDA, Net debt, Core Tax rate and CER are non-GAAP financial measures because they cannot be derived directly from the Group’s Condensed consolidated financial statements.
Management believes that these non-GAAP financial measures, when provided in combination with Reported results, provide investors and analysts with helpful supplementary information to better understand the financial performance and position of the Group on a comparable basis from period to period.
These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP.
Core financial measures are adjusted to exclude certain significant items:
–
Charges and provisions related to our global restructuring programmes, which includes charges that relate to the impact of restructuring programmes on our capitalised manufacturing assets and IT assets
–
Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges relating to IT assets
–
Other specified items, principally comprising acquisition-related costs and credits, which include the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain Other payables arising from intangible asset acquisitions, remeasurement adjustments relating to certain Other payables, debt items assumed from the Alexion acquisition and legal settlements
–
The tax effects of the adjustments above are excluded from the Core Tax charge
Details on the nature of Core financial measures are provided on page 53 of the Annual Report and Form 20-F Information 2025.
Reference should be made to the Reconciliation of Reported to Core financial measures table included in the Financial Performance section in this announcement.
Definitions
Gross Margin is defined as Gross Profit as a percentage of Total Revenue.
EBITDA is defined as Reported Profit before tax after adding back Net finance expense, results from Joint ventures and associates and charges for Depreciation, amortisation and impairment. Reference should be made to the Reconciliation of Reported Profit before tax to EBITDA included in the Financial Performance section in this announcement.
Operating Margin is defined as Operating profit as a percentage of Total Revenue.
Net debt is defined as Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash equivalents, Other investments, and Net derivative financial instruments. Reference should be made to Note 3 ‘Net debt’, included in the Notes to the interim financial statements in this announcement.
The Company strongly encourages investors and analysts not to rely on any single financial measure, but to review AstraZeneca’s financial statements, including the Notes thereto, and other available Company reports, carefully and in their entirety.
Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree to totals.Financial performance
Table 8: Reported Profit and Loss
H1 2026
H1 2025
% Change
Q2 2026
Q2 2025
% Change
$m
$m
Actual
CER
$m
$m
Actual
CER
– Product Sales
28,896
26,670
8
5
14,510
13,795
5
4
– Alliance Revenue
1,699
1,293
31
29
874
654
34
33
Product Revenue
30,595
27,963
9
6
15,384
14,449
6
5
Collaboration Revenue
77
82
(6)
(9)
–
8
n/m
n/m
Total Revenue
30,672
28,045
9
6
15,384
14,457
6
5
Cost of sales
(5,201)
(4,714)
10
3
(2,523)
(2,473)
2
3
Gross profit
25,471
23,331
9
7
12,861
11,984
7
5
Distribution expense
(286)
(278)
3
(3)
(145)
(143)
2
(2)
R&D expense
(7,545)
(6,707)
12
10
(4,053)
(3,548)
14
13
SG&A expense
(10,571)
(9,356)
13
10
(5,651)
(4,864)
16
14
Other operating income & expense
341
192
77
76
152
79
92
93
Operating profit
7,410
7,182
3
2
3,164
3,508
(10)
(13)
Net finance expense
(675)
(636)
6
2
(355)
(371)
(4)
(8)
Joint ventures and associates
(22)
(17)
28
19
(10)
(10)
(8)
(11)
Profit before tax
6,713
6,529
3
2
2,799
3,127
(11)
(13)
Taxation
(1,124)
(1,160)
(3)
(4)
(291)
(679)
(57)
(57)
Tax rate
17%
18%
10%
22%
Profit after tax
5,589
5,369
4
3
2,508
2,448
2
(2)
Earnings per share
$
3.60
$
3.46
4
3
$
1.61
$
1.58
2
(2)
Table 9: Reconciliation of Reported Profit before tax to EBITDA
H1 2026
H1 2025
% Change
Q2 2026
Q2 2025
% Change
$m
$m
Actual
CER
$m
$m
Actual
CER
Reported Profit before tax
6,713
6,529
3
2
2,799
3,127
(11)
(13)
Net finance expense
675
636
6
2
355
371
(4)
(8)
Joint ventures and associates
22
17
28
19
10
10
(8)
(11)
Depreciation, amortisation and impairment
3,295
2,673
23
21
1,928
1,389
39
38
EBITDA
10,705
9,855
9
7
5,092
4,897
4
1
Table 10: Reconciliation of Reported to Core financial measures: H1 2026
Intangible Asset
Amortisation &
Reported
Restructuring
Impairments
Other
Core
% Change
For the half year ended 30 June
$m
$m
$m
$m
$m
Actual
CER
Gross profit
25,471
(3)
16
3
25,487
9
7
– Gross Margin
83%
83%
–
+1pp
Distribution expense
(286)
–
–
–
(286)
3
(3)
R&D expense
(7,545)
57
364
1
(7,123)
9
6
– R&D % of Total Revenue
25%
23%
–
–
SG&A expense
(10,571)
106
2,156
400
(7,909)
9
6
– SG&A % of Total Revenue
34%
26%
–
–
Total operating expense
(18,402)
163
2,520
401
(15,318)
9
6
Other operating income & expense
341
–
–
–
341
82
81
Operating profit
7,410
160
2,536
404
10,510
12
11
– Operating Margin
24%
34%
+1pp
+1pp
Net finance expense
(675)
–
–
54
(621)
20
15
Taxation
(1,124)
(40)
(514)
(111)
(1,789)
10
9
EPS
$
3.60
$
0.08
$
1.31
$
0.22
$
5.21
12
11
(Press release, AstraZeneca, JUL 27, 2026, View Source [SID1234669427])